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Abstract
A convenient, one-pot, two-component synthesis of 2-(1-amidoalkyl)pyridines is reported, based upon the substitution of suitably-
activated pyridine N-oxides by azlactone nucleophiles, followed by decarboxylative azlactone ring-opening. The synthesis obviates
the need for precious metal catalysts to achieve a formal enolate arylation reaction, and constitutes a formally ‘umpoled’ approach
to this valuable class of bioactive structures.
Introduction
Pyridines constitute the most frequently observed class of
heterocycles found in pharmaceutical products [1]. As such,
there is significant demand for synthetic methods that enable
access both to structurally novel and diverse substituted
pyridines for new medicines discovery, and for the develop-
ment of clean, efficient and robust methods for their manufac-
ture on large scale. Pyridines bearing a 1-amidoalkyl substituent
at the 2-position are found in numerous biologically active
natural products such as the antitumour antibiotic kedarcidin
chromophore 1 [2] and the RNA polymerase inhibitor cyclo-
thiazomycin B1 2 [3] (Figure 1). Additionally, the motif is
commonly incorporated into synthetic pharmaceutical candi-
dates, for example in the factor XIa inhibitor 3 [4], the orally-
active renin inhibitor 4 [5] and the threonine tyrosine kinase
inhibitor CFI-401870 (5) [6].
The 2-(1-amidoalkyl)pyridines are almost always synthesised
by acylation of the related 2-(1-aminoalkyl)pyridines,
which can be prepared by reduction of ketimines derived
from 2-acylpyridines [5] or 2-cyanopyridines [6], addition of
carbon nucleophiles to aldimines derived from pyridine-2-
carboxaldehydes [4,7], or nucleophilic substitution of 2-(1-
hydroxyalkyl)pyridines [8]. Alternatively, acyclic precursors
bearing the amidoalkyl (or protected aminoalkyl) substituent
can be applied in de novo construction of the pyridine ring,
exemplified by approaches to the core of the cyclothiazo-
mycins [9,10]. Regardless of the method employed, these are
multistep protocols, frequently employing moisture-sensitive
organometallic agents or reducing agents. In this paper, we
report a new one-pot, two-component synthesis of 2-(1-amido-
alkyl)pyridines that arises from a formally ‘umpoled’ coupling
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Figure 1: Examples of naturally-occurring and synthetic bioactive (amidoalkyl)pyridines.
of an ĭ-(amidoalkyl) anion equivalent with a pyridyl elec-
trophile.
Results and Discussion
Reaction discovery
Our research group has a longstanding interest in the synthesis
of ĭ,ĭ-disubstituted amino acids [11-15], and in particular has
developed methods for the preparation of ĭ-aryl variants by
palladium-catalysed enolate arylation reactions [13-15]. More
recently, we have sought to develop more sustainable methods
for the arylation of amino acid enolate equivalents that avoid
the use of precious metal salts and expensive bespoke ligands,
based upon the electrophilic activation of pyridine N-oxides and
subsequent reaction with acidic carbon nucleophiles [16-20].
Specifically, we have demonstrated that ĭ-pyridyl,ĭ-alkyl-
amino acid derivatives can be prepared in a one-pot three
component coupling between readily-available azlactones and
pyridine N-oxides in the presence of p-toluenesulfonyl chloride
as an activating agent, followed by opening of the arylated
azlactone intermediate with nucleophiles such as alcohols, pri-
mary and secondary amines, and N,O-dialkylhydroxylamines
[21] (Scheme 1). However, in the reaction of alanine-derived
azlactone 6 with 4-methylpyridine N-oxide (7) we found that
when water (in the form of 1 M HCl) was employed as a
nucleophile, the product isolated was in fact the 2-(1-benz-
amidoethyl)-4-methylpyridine (8a), formed by facile decar-
boxylation of the intermediate pyridylamino acid 9 (Nu = OH)
[22,23]. After some minor process optimisation, this product
was isolated in 64% yield.
Scheme 1: Discovery of the azlactone arylation/decarboxylative
hydrolysis approach to 2-(1-amidoalkyl)pyridines.
We recognised that this constitutes a formally ‘umpoled’ [24]
coupling of an ĭ-amino- or amidoalkyl anion [25-27] with a
pyridyl electrophile and hence would complement existing syn-
thetic methods. Given the ready availability of azlactones
bearing differential functionality at C2 and C4, a wide range of
2-(1-amidoalkyl)pyridines should become available and we
elected to exemplify this process.
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Substrate scope
We first examined variation of azlactone substituents in their
reaction with 4-methylpyridine N-oxide (Scheme 2). Pleasingly,
bulkier C4-substituents such as benzyl or isobutyl groups
(derived from phenylalanine and leucine, respectively) were
well tolerated, with isolated yields for the products 8b and 8c of
75% and 69%, respectively. Variation of the C2-azlactone
substituent was also evaluated: swapping a phenyl substituent
for a tert-butyl substituent gave rise to the pivaloyl amide 8d,
albeit in a modest 36% yield.
Scheme 2: Substrate scope of the direct amidoalkylation of pyridine
N-oxides.
Next we examined the behaviour of different 4-substituted pyri-
dine N-oxides (either commercially available or prepared by
oxidation of the corresponding pyridine with m-chloroper-
benzoic acid) with a leucine-derived azlactone. The presence of
bulkier alkyl or aromatic substituents was well tolerated, giving
products 8e and 8f in good yield; however, the presence of an
electron-donating methoxy group led to a lower yield of 8g
(45%). This may reflect the lower electrophilicity of the acti-
vated pyridine N-oxide, which may allow non-productive azlac-
tone decomposition pathways to compete with the desired
substitution.
Finally, we examined the regiochemical outcome of the reac-
tion of pyridine N-oxides with other substitution patterns. Pyri-
dine N-oxide itself delivered a ca. 2:1 mixture of the separable
4- and 2-substituted isomers of 8h in overall 60% yield. Statisti-
cally corrected for the available reactive positions, this reflects
an inherent 4:1 preference for reaction at the 4-position, which
may in part be due to steric hindrance at the C2-positions by the
activated N-oxide. The high C4-selectivity was also evident in
the formation of a >5:1 selectivity for the formation of the 2,4-
isomer of 8i over the 2,6-isomer when 2-methylpyridine
N-oxide was used as substrate. Finally, the use of 3-methylpyri-
dine N-oxide gave a ca. 7:2:2 mixture of 3,4-:2,3-:2,5-isomers
of 8j. Although the regioselectivities are not exceptionally high,
the ready chromatographic separation of the various isomers
makes this a synthetically tractable approach to 4-substituted
(1-amidoalkyl)pyridine derivatives.
Conclusion
In summary, we have demonstrated a new umpoled disconnec-
tion for the one-pot, two-component synthesis of 2-(1-
amidoalkyl)pyridines using simple, widely-available coupling
partners without the requirement for expensive or critically-
available reagents and catalysts. The reactions display good
generality over 10 examples (36–75% yields, average 60%).
Given the medicinal relevance of the (amidoalkyl)pyridine
products, and the convergent nature of the reaction, we believe
that the method should find ready application in the concise
synthesis of bioactive molecules.
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